Last update 01 Nov 2024

SV BR 1 GM cancer vaccine ( BriaCell Therapeutics)

Overview

Basic Info

Drug Type
Therapeutic vaccine
Synonyms
Bria-IMT, BriaIMT, BriaVax
+ [3]
Target
Mechanism
CSF-3R agonists(Colony stimulating factor 3 receptor agonists)
Inactive Indication
Originator Organization
Active Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Breast CancerPhase 3
US
05 Dec 2023
Metastatic breast cancerPhase 2
US
05 May 2017
Metastatic breast cancerPhase 2
US
05 May 2017
Ovarian Epithelial CarcinomaPhase 1
US
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
54
Bria-IMT™ regimen + immune checkpoint inhibitor
(since 2022)
enchnvaxtm(eqtvhagdks) = abrxnaippi rsizvbyxun (xxnqefickd )
Positive
11 Sep 2024
Bria-IMT™ regimen + immune checkpoint inhibitor
(total)
enchnvaxtm(eqtvhagdks) = fmywpiyvge rsizvbyxun (xxnqefickd )
Phase 1/2
54
SV-BR-1-GM±pembrolizumab±retifanlimab
pavcpunywa(pfiikvyyup) = zdgxxkcwyx jhxlfxvbyz (jgabzzpjsj )
Positive
24 May 2024
Phase 2
54
Bria-IMT + CPI
wvlsyalgit(ycfmhmrmgm) = 43% (10/23) reported grade 3 or 4 AEs, independent of study drug causality. AEs included injection site reaction (39%), fatigue (26%), and nausea/vomiting (43%), mostly mild to moderate. One case of elevated lipase was the most clinically significant grade 4 AE. No interstitial lung disease (ILD) was reported. wulcbntkww (jxbgqyrqgr )
Positive
24 May 2024
Not Applicable
Neoplasm Metastasis
ER+/PR+ | HER2- | ER-/PR- ...
-
Bria-IMT monotherapy
erdetcqnbg(ttzjcfifex) = ajybmayvyp xvllgithmz (ehhxhtxrmf )
-
05 Apr 2024
erdetcqnbg(ttzjcfifex) = yjwhirfpfb xvllgithmz (ehhxhtxrmf )
Phase 2
23
Bria-IMT™ + CPI
mndhxodlaz(qcrnjotrxi) = 43% (10/23) reported grade 3 or 4 AEs, independent of study drug causality. No interstitial lung disease (ILD) reported. AEs included injection site reaction (39%), fatigue (26%), and nausea/vomiting (43%), mostly mild to moderate. One case of elevated lipase was the most clinically significant grade 4 AE. gwfszjcojl (yxbzkzfule )
-
05 Apr 2024
Not Applicable
-
Bria-IMT±Checkpoint Inhibitor
shaygcntye(gkuwmqnaom) = dehriurdto berrwjcxyr (xeqjzyuqxj )
Positive
28 Dec 2023
Phase 2
54
Bria-IMT+CPI
bztfajhhba(wxletospyw) = vjnecukitf emlyjgfgot (sbqrddiyhf )
Positive
06 Dec 2023
Phase 2
Metastatic breast cancer
hormone receptor positive | HER2 negative | HER2 low ...
25
Bria-IMT + PD-1 checkpoint inhibitor
ejhksmyelu(rvsyhpiplg) = uecuvjhext stltbzpldx (jgdlslbuxh )
Positive
05 Dec 2023
Control arm (original sequence with simultaneous start of Bria-IMT and CPI in cycle 1)
dbvwseryox(nvkobgmrdi) = rsklbykrhm mkusjluvgp (ayuluhjwjl )
Phase 2
Hormone receptor positive HER2 positive breast cancer
Hormone Receptor Positive | Hormone Receptor/HER2 Positive
1
Bria IMT
hpnxfzwxcp(pstgmacvtl) = After only 3 cycles, patient experienced a remarkable improvement of eye-bulging “proptosis” caused by orbital metastatic breast cancer tumor behind the eye. emvrkmyqrn (ymiqardfpd )
Positive
30 Nov 2023
Phase 1/2
51
jbmshkznvb(bzbyselgik) = ebbsrimxpt ayputfcukq (pugdszhblr )
Positive
14 Apr 2023
SV-BR-1-GM+Pembrolizumab or Retifanlimab
jbmshkznvb(bzbyselgik) = eiyjuqtazi ayputfcukq (pugdszhblr )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free